The financial results announcement, coupled with the sale of INBRX-101 to a major pharmaceutical company like Sanofi, is likely to positively impact Inhibrx's stock in the short term. The sale could be seen as a strategic move to streamline operations and focus on other pipeline products, potentially boosting investor confidence.